Abdominal obesity and the metabolic syndrome: A surgeon's perspective

Canadian Journal of Cardiology

Volumn 24, Issue SUPPL.D, 2008, Pages 19D-23D

  Mathieu, Patrick ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Cardiac surgery; Metabolic syndrome; Valvular heart disease; Visceral obesity

Indexed keywords

HEART DISEASE; HEART SURGERY; HUMAN; METABOLIC SYNDROME X; METHODOLOGY; MORBIDITY; OBESITY; PROGNOSIS; REVIEW; RISK FACTOR;

CARDIAC SURGICAL PROCEDURES; HEART DISEASES; HUMANS; METABOLIC SYNDROME X; MORBIDITY; OBESITY; PROGNOSIS; RISK FACTORS;

EID: 55949114468     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)71045-6     Document Type: Conference Paper

References (49)

1. Zimmet P. Diabesity - the biggest epidemic in human history. MedGenMed 2007;9:39.
2. Brochu M, Starling RD, Tchernof A, Matthews DE, Garcia-Rubi E, Poehlman ET. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J Clin Endocrinol Metab 2000;85:2378-84.
3. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-7.
4. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: A global public health problem and a new definition. J Atheroscler Thromb 2005;12:295-300.
5. Unger RH. Longevity, lipotoxicity and leptin: The adipocyte defense against feasting and famine. Biochimie 2005;87:57-64.
6. Mathieu P, Despres JP, Pibarot P. The 'valvulo-metabolic' risk in calcific aortic valve disease. Can J Cardiol 2007;23(Suppl B):32B-9B.
7. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP. Visceral obesity and the heart. Int J Biochem Cell Biol 2008;40:821-36.
8. O'Brien KD. Epidemiology and genetics of calcific aortic valve disease. J Investig Med 2007;55:284-91.
9. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: An echocardiographic study of a random population sample. J Am Coll Cardiol 1993;21:1220-5.
10. Mathieu P, Voisine P, Pepin A, Shetty R, Savard N, Dagenais F. Calcification of human valve interstitial cells is dependent on alkaline phosphatase activity. J Heart Valve Dis 2005;14:353-7.
11. Charest A, Pepin A, Shetty R, et al. Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart 2006;92:1844-9.
12. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994;90:844-53.
13. Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: An active atheroinflammatory process. Curr Opin Lipidol 2007;18:483-91.
14. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4.
15. Moura LM, Zamorano J, Perez-Oteyza C, Rocha-Gonclves F, Rajamannan NM. The role of statins in aortic stenosis. Myth or reality? Rev Port Cardiol 2007;26:51-62.
16. Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensinconverting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110:1291-5.
17. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002;40:1723-30.
18. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
19. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-61.
20. O'Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002;106:2224-30.
21. O'Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensinconverting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005;165:858-62.
22. Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 2006;47:2229-36.
23. Mohty D, Pibarot P, Despres JP, et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008;28:187-93.
24. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999;25:199-211.
25. Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996;123:43-56.
26. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992;93:189-99.
27. Lemieux I, Laperriere L, Dzavik V, Tremblay G, Bourgeois J, Despres JP. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 2002;162:363-71.
28. Yoshino G, Hirano T, Kazumi T. Treatment of small dense LDL. J Atheroscler Thromb 2002;9:266-75.
29. Schoen FJ, Levy RJ. Calcification of tissue heart valve substitutes: Progress toward understanding and prevention. Ann Thorac Surg 2005;79:1072-80.
30. Ruel M, Kulik A, Rubens FD, et al. Late incidence and determinants of reoperation in patients with prosthetic heart valves. Eur J Cardiothorac Surg 2004;25:364-70.
31. Tomazic BB, Brown WE, Schoen FJ. Physicochemical properties of calcific deposits isolated from porcine bioprosthetic heart valves removed from patients following 2-13 years function. J Biomed Mater Res 1994;28:35-47.
32. Manji RA, Zhu LF, Nijjar NK, et al. Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection. Circulation 2006;114:318-27.
33. Farivar RS, Cohn LH. Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J Thorac Cardiovasc Surg 2003;126:969-75.
34. Briand M, Pibarot P, Despres JP et al. Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 2006;114(1 Suppl):I512-7.
35. O'Brien KD. Do bioprosthetic aortic valves deteriorate more rapidly in patients with the metabolic syndrome? Nat Clin Pract Cardiovasc Med 2007;4:192-3.
36. Antonini-Canterin F, Zuppiroli A, Popescu BA, et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 2003;92:1479-82.
37. Antonini-Canterin F, Popescu BA, Zuppiroli A, Nicolosi GL. Are statins effective in preventing bioprosthetic aortic valve failure? A need for a prospective, randomized trial. Ital Heart J 2004;5:85-8.
38. Nalysnyk L, Fahrbach K, Reynolds MW, Zhao SZ, Ross S. Adverse events in coronary artery bypass graft (CABG) trials: A systematic review and analysis. Heart 2003;89:767-72.
39. Echahidi N, Pibarot P, Despres JP, et al. Metabolic syndrome increases operative mortality in patients undergoing coronary artery bypass grafting surgery. J Am Coll Cardiol 2007;50:843-51.
40. Echahidi N, Mohty D, Pibarot P, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 2007;116(11 Suppl):I213-I219.
41. Unger RH. Lipid overload and overflow: Metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003;14:398-403.
42. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319-36.
43. Unger RH. Hyperleptinemia: Protecting the heart from lipid overload. Hypertension 2005;45:1031-4.
44. Iacobellis G, Sharma AM. Adiposity of the heart. Ann Intern Med 2006;145:554-5.
45. Marchington JM, Mattacks CA, Pond CM. Adipose tissue in the mammalian heart and pericardium: Structure, foetal development and biochemical properties. Comp Biochem Physiol B 1989;94:225-32.
46. Wang MY, Unger RH. Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone. Am J Physiol Endocrinol Metab 2005;288:E216-21.
47. McGavock JM, Victor RG, Unger RH, Szczepaniak LS. Adiposity of the heart, revisited. Ann Intern Med 2006;144:517-24.
48. Baker AR, Silva NF, Quinn DW, et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006;5:1.
49. Tanumihardjo SA, Anderson C, Kaufer-Horwitz M, et al. Poverty, obesity, and malnutrition: An international perspective recognizing the paradox. J Am Diet Assoc 2007;107:1966-72.